SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease ...

SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated• Phase 2 ...

PYC Therapeutics Shares Jump 5% as Investors Bet on Kidney Disease Data From RNA Drug Developer This Year

PYC Therapeutics shares gained 5.1% as investors looked ahead to clinical data for PYC-003, an experimental RNA treatment for inherited polycystic kidney disease.
pharmadispatch

PYC to present early polycystic kidney disease trial data at US nephrology conference

Perth-based company PYC Therapeutics will take early human data on its polycystic kidney disease drug to the American Society of Nephrology conference in Denver on 22 October.
RTTNews

SCYNEXIS Reports Favorable Phase 1 Results For ADPKD Drug

The Phase 1 study enrolled 25 healthy participants across three cohorts. The initial cohort received a single 500 mg dose under fed and fasted conditions, while subsequent cohorts received 750 mg once ...